New drug trial aims to slow vision loss in rare genetic eye disease
NCT ID NCT06388083
Summary
This clinical trial is testing whether a medication called tinlarebant can slow the progression of Stargardt disease, a genetic condition that causes vision loss. The study involves 60 participants who will take either the drug or a placebo daily for two years while researchers measure changes in their vision and eye lesions. The goal is to determine if tinlarebant is safe and effective at controlling the disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STGD1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Belite Study Site
RECRUITINGKobe, Japan
-
Belite Study Site
RECRUITINGKyoto, Japan
-
Belite Study Site
RECRUITINGTokyo, Japan
-
Belite Study Site - US01
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US02
RECRUITINGDurham, North Carolina, 27705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US03
RECRUITINGDallas, Texas, 75231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US04
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US05
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US06
RECRUITINGMiami, Florida, 33136, United States
Contact Email: •••••@•••••
-
Belite Study Site - US07
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US08
RECRUITINGPhoenix, Arizona, 85020, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US09
RECRUITINGSan Francisco, California, 94158, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US10
RECRUITINGWestbury, New York, 11590, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US11
RECRUITINGEdina, Minnesota, 55435, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US12
RECRUITINGThe Woodlands, Texas, 77384, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US13
RECRUITINGAustin, Texas, 78705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Belite Study Site - US14
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UK01 Belite Study Site
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.